文献

  1. Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991;266:7779-83.
  2. Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 1991;266:7774-8.
  3. 小山信吾, 加藤丈夫. 脳腱黄色腫症の病態. 臨床神経 2016;56:821-6.
  4. 関島良樹. 脳腱黄色腫症の疾患概念と臨床像の多様性. 神経内科 2017;86:346-51.
  5. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5.
  6. Sekijima Y, Koyama S, Yoshinaga T, et al. Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet 2018;63:271-80.
  7. Appadurai V, DeBarber A, Chiang PW, et al. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab 2015;116:298-304.
  8. Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000;123:908-19.
  9. Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 2011;18:1203-11.
  10. Clayton PT, Verrips A, Sistermans E, et al. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 2002;25:501-13.
  11. Mignarri A, Gallus GN, Dotti MT, et al. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 2014;37:421-9.
  12. Lee MH, Hazard S, Carpten JD, et al. Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 2001;42:159-69.
  13. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984;311:1649-52.
  14. Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 2009;123:143-7.
  15. Inanloorahatloo K, Zand Parsa AF, Huse K, et al. Mutation in CYP27A1 identified in family with coronary artery disease. Eur J Med Genet 2013;56:655-60.
  16. Valdivielso P, Calandra S, Duran JC, et al. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med 2004;255:680-3.
  17. Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry 2013;3:e302.
  18. Soffer D, Benharroch D, Berginer V. The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol 1995;90:213-20.
  19. Barkhof F, Verrips A, Wesseling P, et al. Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 2000;217:869-76.
  20. Sperhake JP, Matschke J, Orth U, et al. Sudden death due to cerebrotendinous xanthomatosis confirmed by mutation analysis. Int J Legal Med 2000;113:110-3.
  21. Kato H, Koyabu S, Aoki S, et al. An autopsy case of gallbladder cancer developing in a Japanese man with cerebrotendinous xanthomatosis: genetic analysis of the sterol 27-hydroxylase and p53 genes. Pathology 2003;35:141-4.
  22. Pilo de la Fuente B, Ruiz I, Lopez de Munain A, et al. Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 2008;255:839-42.
  23. Inoue K, Kubota S, Seyama Y. Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun 1999;256:198-203.
  24. Verrips A, van Engelen BG, ter Laak H, et al. Cerebrotendinous xanthomatosis. Controversies about nerve and muscle: observations in ten patients. Neuromuscul Disord 2000;10:407-14.
  25. Pilo B, de Blas G, Sobrido MJ, et al. Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve 2011;43:531-6.
  26. Ginanneschi F, Mignarri A, Mondelli M, et al. Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol 2013;260:268-74.
  27. Verrips A, Nijeholt GJ, Barkhof F, et al. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain 1999;122:1589-95.
  28. Abe R, Sekijima Y, Kinoshita T, et al. Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion. J Spinal Cord Med 2016;39:726-9.
  29. Yanagihashi M, Kano O, Terashima T, et al. Late-onset spinal form xanthomatosis without brain lesion: a case report. BMC Neurol 2016;16:21.
  30. Nicholls Z, Hobson E, Martindale J, et al. Diagnosis of spinal xanthomatosis by next-generation sequencing: identifying a rare, treatable mimic of hereditary spastic paraparesis. Pract Neurol 2015;15:280-3.
  31. Saute JA, Giugliani R, Merkens LS, et al. Look carefully to the heels! A potentially treatable cause of spastic paraplegia. J Inherit Metab Dis 2015;38:363-4.
  32. von Bahr S, Bjorkhem I, Van’t Hooft F, et al. Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr 2005;40:481-6.
  33. Pierre G, Setchell K, Blyth J, et al. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 2008;31 Suppl 2:S241-5.
  34. De Stefano N, Dotti MT, Mortilla M, et al. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 2001;124:121-31.
  35. Yoshinaga T, Sekijima Y, Koyama S, et al. Clinical and Radiological Findings of a Cerebrotendinous Xanthomatosis Patient with a Novel p.A335V Mutation in the CYP27A1 Gene. Intern Med 2014;53:2725-9.
  36. 吉長恒明, 関島良樹. 脳腱黄色腫症の画像所見の特徴. 神経内科 2017;86:368-73.
  37. Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci 2006;27:143-9.
  38. van Heijst AF, Wevers RA, Tangerman A, et al. Chronic diarrhoea as a dominating symptom in two children with cerebrotendinous xanthomatosis. Acta Paediatr 1996;85:932-6.
  39. Nakamura T, Matsuzawa Y, Takemura K, et al. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 1991;40:741-6.
  40. Martini G, Mignarri A, Ruvio M, et al. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 2013;92:282-6.
  41. van Heijst AF, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 1998;157:313-6.
  42. Huidekoper HH, Vaz FM, Verrips A, et al. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. Eur J Pediatr 2016;175:143-6.
  43. Lewis B, Mitchell WD, Marenah CB, et al. Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis. Br Med J (Clin Res Ed) 1983;287:21-2.
  44. Batta AK, Salen G, Tint GS. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism 2004;53:556-62.
  45. Verrips A, Wevers RA, Van Engelen BG, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999;48:233-8.
  46. Luyckx E, Eyskens F, Simons A, et al. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg 2014;118:9-11.
  47. Mimura Y, Kuriyama M, Tokimura Y, et al. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci 1993;114:227-30.
  48. Dotti MT, Lutjohann D, von Bergmann K, et al. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. Neurol Sci 2004;25:185-91.
  49. Ito S, Kuwabara S, Sakakibara R, et al. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 2003;216:179-82.
  50. Berginer VM, Salen G. LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci 1994;121:229-32.
  51. 村松英俊, 齋藤昌美, 梁井まり，他. 脳腱黄色腫症に対する外科的治療の経験. 日本形成外科学会会誌 2009;29:27-33.
  52. 梶ひろみ, 梶彰吾, 鶴田純二，他. 巨大なアキレス腱黄色腫をfree flapで再建した脳腱黄色腫症の1例. 形成外科 1993;36:693-9.
  53. Arlazoroff A, Roitberg B, Werber E, et al. Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia 1991;32:657-61.
  54. Koyama S, Kawanami T, Tanji H, et al. A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg 2012;114:1021-3.
  55. Su CS, Chang WN, Huang SH, et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 2010;25:452-8.
  56. Lagarde J, Sedel F, Degos B. Blepharospasm as a new feature of cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2013;19:764-5.
  57. Yahalom G, Tsabari R, Molshatzki N, et al. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 2013;36:78-83.